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Common genetic variations in Wnt signaling genes
have been associated with metabolic syndrome and
diabetes by mechanisms that are poorly understood.
A rare nonconservative mutation in Wnt coreceptor
LRP6 (LRP6R611C) has been shown to underlie auto-
somal dominant early onset coronary artery disease,
type 2 diabetes, and metabolic syndrome. We exam-
ined the interplay between Wnt and insulin signaling
pathways in skeletal muscle and skin fibroblasts of
healthy nondiabetic LRP6R611C mutation carriers.
LRP6 mutation carriers exhibited hyperinsulinemia
and reduced insulin sensitivity compared to noncar-
rier relatives in response to oral glucose ingestion,
which correlated with a significant decline in tissue
expression of the insulin receptor and insulin
signaling activity. Further investigations showed
that the LRP6R611C mutation diminishes TCF7L2-
dependent transcription of the IR while it increases
the stability of IGFR and enhances mTORC1 activity.
These findings identify theWnt/LRP6/TCF7L2 axis as
a regulator of glucose metabolism and a potential
therapeutic target for insulin resistance.
INTRODUCTION
Despite widespread recognition of metabolic syndrome as
amajor risk factor for coronary artery disease and diabetes (Mal-
lika et al., 2007; Mottillo et al., 2010; Vaidya et al., 2010), its
underlying causes have remained poorly understood (Gade
et al., 2010). Genome-wide association studies have linked poly-
morphisms within the gene encoding Wnt transcription cofactor
TCF7L2 to risk for type 2 diabetes (DM2) in independent large
cohorts (Saxena et al., 2006; Wang et al., 2007). Genetic varia-Cell Mtions of the Wnt5B gene have been similarly associated with
susceptibility to type 2 diabetes (Kanazawa et al., 2004). These
findings have implicated altered Wnt signaling in impaired
glucose metabolism and diabetes.
While the associations between these genetic variants and
type 2 diabetes appear as extremely robust, their effects on
cellular insulin response are not understood (Liu et al., 2009;
Rasmussen-Torvik et al., 2009). In principal, the biological
effects imparted by the common polymorphisms are too small
to be measurable in artificial cell systems and animal models.
Disruptions of the genes that encode Wnt signaling proteins in
animal models have similarly indicated the critical role of this
pathway in glucose homeostasis (Leng et al., 2010; Pagel-
Langenickel et al., 2008; Summers et al., 1999). However, the
demonstrated effects of Wnt/b-catenin on insulin signaling
(Abiola et al., 2009; Liu et al., 2011, 2012) and hepatic gluconeo-
genesis have often been inconsistent (Liu et al., 2011). These
discrepancies once again reveal a recognized problem with
animal models for the study of glucose homeostasis, indicating
an urgent need for human studies.
The canonical Wnt signaling pathway consists of cascades of
events that initiate after Wnt proteins bind to the cell-surface
receptor Frizzled and its coreceptors LRP5 and LRP6, triggering
inactivation of GSK3b and stabilization of b-catenin (Bilic et al.,
2007; Go and Mani, 2012; Schweizer and Varmus, 2003). The
final steps include translocation of b-catenin from cytoplasm
to the nucleus, where it interacts with the TCF/LEF family of
transcription activators to promote gene expression. We have
recently reported a large outlier kindred in whom a rare non-
conservative loss-of-function mutation in LRP6 (LRP6R611C)
underlies a monogenic form of early onset coronary artery
disease, hypertension, dyslipidemia, and diabetes, suggesting
insulin resistance (Mani et al., 2007). Genetic studies of rare
families segregating single-gene mutations that impart very
large effects on disease pathogenesis have shown the greatest
potential to identify genes and pathways that have paved the
way for discovery of novel and potent therapeutics (Goldstein
and Brown, 1973; Hobbs et al., 1992, 1989). Accordingly, theetabolism 17, 197–209, February 5, 2013 ª2013 Elsevier Inc. 197
Figure 1. Skeletal Muscle Insulin Resistance in LRP6R611C Mutation Carriers
(A) LRP6R611C mutation carriers (R611C), with or without impaired glucose tolerance (IGT and NGT), had higher circulating glucose levels in response to oral
glucose load compared to non-carrier relatives (WT).
(B) Serum insulin levels were higher in LRP6R611C mutation carriers compared to non-carrier relatives during the last stages of the OGTT.
(C) The insulin sensitivity index (ISI) was significantly lower in LRP6R611C mutation carriers with NGT compared to non-carriers.
(D and E) IR mRNA expressions (D) and IR protein levels and AKT phosphorylation (E) were significantly lower in mutation carriers with NGT (lanes 3 and 4) and
DM2 (lanes 5 and 6) compared to noncarriers (lanes 1 and 2).
(F and G) Quantification of IR (F) and pAKT (G) by densitometry (*p < 0.05, **p < 0.005). Error bars represent SD.
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Wnt/LRP6 Regulation of IR and IGFRidentification of a mutation with major effect in the Wnt corecep-
tor LRP6 provided us with an exceptional opportunity to study
the role of Wnts and their downstream signaling proteins in
glucose metabolism.
The current study was undertaken to examine the interplay
between Wnt and insulin signaling pathways and its potential
role in the development of insulin resistance and type 2 diabetes.
For this purpose we examined young, healthy nondiabetic
LRP6R611C mutation carriers and their nonmutation carrier rela-
tives, matched for gender, weight, and physical activity levels,
for the presence of impaired insulin sensitivity. Insulin signaling
was investigated in the skeletal muscle, the major organ for
glucose disposal, and the skin fibroblast cultures of the mutation
carriers and noncarrier relatives after they underwent extensive
clinical evaluations and oral glucose tolerance tests (OGTT).
These studies were complemented by comprehensive dissec-
tion of metabolic pathways in the cultured skin fibroblasts of
LRP6R611C mutation carriers and their unaffected relatives as
well as in vitro expression systems.
RESULTS
LRP6R611C Mutation Impairs Glucose Tolerance and
Insulin Response
Eight LRP6R611C mutation carriers (n = 8) and noncarriers (n = 7)
who denied a history of diabetes participated in the study. The
clinical characteristics are summarized in the Table S1. Overall,198 Cell Metabolism 17, 197–209, February 5, 2013 ª2013 Elsevier Inthe mutation carriers had significantly higher low-density lipo-
protein (LDL) and triglyceride levels and similar BMI and serum
high-density lipoprotein (HDL) as compared to noncarrier rela-
tives (Mani et al., 2007).
All 15 family members recruited for the study underwent
an OGTT prior to skeletal muscle and skin fibroblast biopsies.
Skeletal muscle and skin biopsies were also obtained from
mutation carriers with diabetes for comparison. Both serum
glucose and insulin levels during 2 hr OGTT were significantly
higher in mutation carriers compared to noncarriers (Figures
1A and 1B). Analysis of the plasma glucose levels at 2 hr postglu-
cose ingestion in mutation carriers revealed that one subject
had developed diabetes (DM, blood glucose greater than
200 mg/dl at 2 hr).
Circulating glucose levels in the mutation carriers were similar
to noncarrier relatives in the first 45 min following glucose inges-
tion, but subsequently increased to higher levels between 60 and
120 min as compared to noncarrier relatives (Figure 1A). The
majority of patients (four male, one female) still had normal
glucose tolerance tests by definition (NGT; Table S1). Only two
patients (one male, one female) had impaired glucose tolerance
(IGT, blood glucose between 140 mg/dl and 200 mg/dl at 2 hr).
Fasting plasma glucose and insulin levels prior to the 2 hr oral
glucose tolerance in the NGT LRP6R611C mutation carriers
were normal and comparable to the seven noncarrier relatives
(five male, two female) who were matched for age, weight, and
physical activity levels (Table S1). These findings are consistentc.
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glucose levels in the NGT probands at 2 hr (118 ± 2 mg/dl)
were significantly higher than those in noncarrier relatives
(76 ± 12mg/dl) (p < 0.001). Plasma insulin levels were also initially
similar but rose to significantly higher levels in the mutation
carriers between 90 and 120 min (Figure 1B). Despite elevated
insulin levels, the delayed decay of the plasma glucose in
LRP6 mutation carriers is consistent with a subclinical skeletal
muscle insulin resistance as described by prior studies (Abdul-
Ghani et al., 2007). Accordingly, the insulin sensitivity index
(ISI) was reduced in the mutation carriers with NGT (5.17 ±
1.18) as compared to noncarriers (7.7 ± 1.2) (p < 0.005) (Fig-
ure 1C). The remaining three mutation carriers (two IGT and
one DM) also had diminished ISI as expected (4.9 ± 0.77;
p < 0.005). Taken together, these findings suggested signifi-
cantly greater predisposition to skeletal muscle insulin resis-
tance in mutation carriers versus their noncarrier relatives and
prompted the study of insulin signaling in the skeletal muscles
of the mutation carriers and noncarrier relatives.
Three male mutation carriers (subjects III-1, III-2, and III-7 in
Table S1) and three matched noncarrier controls also agreed
to participate in a hyperinsulinemic-euglycemic clamp study.
This study was carried out to confirm OGTT findings. The
glucose infusion rate required to maintain euglycemia during
the higher insulin dose clampwas diminished in each of the three
mutation carriers compared to noncarriers (233 ± 25 mg/m2/min
versus 396 ± 56mg/m2/min, respectively; p = 0.01). Accordingly,
the glucose disposal rate (GDR) during high dose insulin in muta-
tion carriers (with or without IGT or diabetes) was significantly
lower compared to noncarriers (256 ± 23 mg/m2/min versus
443 ± 79 mg/m2/min, respectively; p < 0.05) (Figure S1). While
the number of subjects studied was small, the differences
betweenmutation carriers and noncarriers were drastic. Accord-
ingly, a power calculation estimated the number of subjects to be
studied as less than three (see Experimental Procedures). The
sample size was too small to exclude hepatic insulin resistance
based on hepatic glucose output (Figure S1B) or OGTT. Taken
together, these findings further supported the presence of skel-
etal muscle insulin resistance in LRP6R611C mutation carriers.
LRP6R611C Impairs Skeletal Muscle IR Expression and
Insulin Signaling Activity
To examine the effect of the LRP6R611C mutation on insulin
signaling prior to development of impaired glucose tolerance,
tissues (skeletal muscle and fibroblasts) from individuals with
NGT (n = 5) and five matched noncarrier relatives were
compared for expression of genes involved in insulin signaling.
The qPCR demonstrated a 60% reduction in skeletal muscle
insulin receptor (IR) mRNA in LRP6R611C mutation carriers as
compared to noncarriers (p < 0.005; Figure 1D) suggesting
impaired transcription of the IR. Accordingly, western blot anal-
ysis showed a >50% reduction of protein abundances for IR-b in
the skeletal muscles of the mutation carriers compared to
noncarriers (Figures 1E and 1F). As anticipated, IR expression
was also reduced in the skeletal muscles of LRP6R611Cmutation
carriers with diabetes. The analysis also showed reduced AKT
phosphorylation in the mutation carriers as compared to noncar-
riers (Figures 1E and 1G). Taken together, these results suggest
major impairment in the initial step of the skeletal muscle insulinCell Msignaling in LRP6R611Cmutation carriers compared to noncarrier
relatives.
Insulin Signaling Is Impaired in Cultured Fibroblasts of
the LRP6R611C Mutation Carriers
LRP6 phosphorylation in response toWnt stimulation was signif-
icantly lower in the skin fibroblasts ofLRP6R611Cmutation carriers
compared to noncarriers without having significant effects on
adipogenic differentiation (Figures S2A and S2B). Analogous to
the skeletal muscle, the IRmRNA (Figure 2A) and protein (Figures
2B and 2D) expression levels were reduced in the fibroblasts of
LRP6R611C mutation carriers compared to their noncarrier rela-
tives. To assess the impact of these changes on downstream
signaling, skin fibroblast cultures obtained from NGT mutation
carriers and noncarrier relatives were stimulated with insulin.
Insulin-stimulated activations of IRS-1, AKT, and GSK3b were
significantly reduced in fibroblasts of LRP6R611C mutation
carriers compared to noncarriers (Figures 2C and 2E–2G).
LRP6 Is Required for Normal Expression of the IR
LRP6R611C phosphorylation in response to Wnt3a is significantly
reduced in skin fibroblasts of mutation carriers compared to
wild-type LRP6 (Figure S2, upper and lower panels). This
confirmed our earlier findings that the LRP6R611C mutation is a
loss-of-function mutation. To examine whether LRP6 is required
for normal expression of the IR, LRP6 was knocked down by
RNA interference. LRP6-specific shRNA diminished expression
ofLRP6bymore than90%(Figure3A). IRmRNAandprotein levels
in LRP6 knockdown 3T3L1 cells were reduced by greater than
50% (p < 0.05) (Figures 3A–3C). This corresponded to markedly
reduced IRS-1 and AKT activities in response to insulin in the
differentiated LRP6 knockdown 3T3L1 cells (Figures 3D–3E).
Treatment of 3T3L1 cells with actinomycin D and cylcoheximide
did not alter IR protein levels (data not shown), indicating that
the regulation of IR by LRP6 is specifically at transcriptional levels.
Thesefindingsonceagainunderscore thecritical roleofLRP6 in IR
transcription and maintaining the integrity of the insulin signaling.
Canonical Wnt Signaling Enhances IR Expression
Given the above findings, a broader question was raised as to
whether IR transcription is regulated by Wnt stimulation. To
address this issue, mRNA and protein expressions were
measured at different time points in 3T3L1 cells stimulated
with Wnt3a (Figures 4A–4C). IR mRNA expression increased
continuously until it reached a maximum after 8 hr. IR protein
began to increase 6 hr after stimulation and reached a maximum
after 8 hr. Wnt stimulation completely failed to increase IR
expression when LRP6 was knocked down (Figure 4D). We
then treated LRP6 knockdown 3T3L1 cells with GSK3b antago-
nist LiCl for 24 hr to rescue IR expression. Upon Wnt3a stimula-
tion IR expression was significantly increased in cells treated
with LiCl versus those untreated (Figure 4E). This finding strongly
suggests that LRP6 mediates Wnt3a-dependent IR transcrip-
tion. Earlier studies have shown that LRP6 behaves as a physio-
logical inhibitor of the noncanonical Wnt signaling and many of
the phenotypes of LRP6 knockout mice are due to gain of func-
tion in the noncanonical pathway (Bryja et al., 2009). To examine
the effect of noncanonical pathway on IR transcription, 3T3L1
cells were stimulated with Wnt5a. Wnt5a failed to alter IRetabolism 17, 197–209, February 5, 2013 ª2013 Elsevier Inc. 199
Figure 2. Reduced IR Expression and
Insulin Response in the Skin Fibroblasts of
LRP6R611C Mutation Carriers
(A and B) IR mRNA (A) and IR-b protein levels (B)
were significantly reduced in skin fibroblasts of
LRP6R611C mutation carriers with NGT (lanes 3
and 4) or diabetes (lanes 5 and 6) compared to
noncarrier relatives.
(C) Insulin response assessed by phosphorylation
of IRS-1, AKT, and GSK3b was significantly
impaired in the skin fibroblasts of the LRP6R611C
mutation carriers compared to noncarrier rela-
tives.
(D–G) Quantification of IR (D), p-IRS-1 (E), p-AKT
(F), and p-GSK3b (G) by densitometry. Open circle
represents the control, and black square repre-
sents the mutant. (*p < 0.05, **p < 0.005, ***p <
0.001). Error bars represent SD.
Cell Metabolism
Wnt/LRP6 Regulation of IR and IGFRexpression (Figure 4F). The role of canonical Wnt signaling in
inducing IR expression was further explored by knockdown of
b-catenin, an integral component of this pathway. Accordingly,
the b-catenin knockdown by RNA interference led to significant
reduction in expression of the IR protein (Figure 4G).
Transcription of the IR Is Regulated by TCF7L2
We examined the expression levels of high-mobility group
protein (HMGI[Y]) in the skeletal muscle and skin fibroblasts of
mutation carriers and their unaffected family members. HMGI(Y)
is encoded by HMGA and regulates IR transcription (Brunetti
et al., 2001). Mice deficient for HMGA1 express low levels of
the IR in insulin-sensitive tissue like the skeletal muscle and
are diabetic (Foti et al., 2005). HMGA has been shown to be
inducible by Wnt/b-catenin in different malignant cells. There
were no differences at mRNA or protein expression levels of
HMGI(Y) in the skeletal muscle or skin fibroblasts of mutation
carriers and their unaffected relatives (Figures S3A–S3F).
TCF7L2 is an HMG box-containing transcription factor, which
is downstream of Wnt/b-catenin. Common genetic variations of
TCF7L2 have been associated with risk for type 2 diabetes in
numerous independent populations across the world (Scott
et al., 2007; Sladek et al., 2007). These variations cause reduced
protein expression (Shu et al., 2009), but its effect on insulin
signaling is not understood. The IR promoter has a number of
putative binding sites for the TCFs. TCF7L2 knockdown by RNA200 Cell Metabolism 17, 197–209, February 5, 2013 ª2013 Elsevier Inc.interference in both 3T3L1 preadipocytes
and human skin fibroblasts abolished the
stimulatory effect of Wnt3a on IR tran-
scription (Figures 5A and 5B). In contrast,
overexpression of TCF7L2 in 3T3L1 cells
caused a greater than 3-fold increase in
IR expression (p < 0.01; Figure 5C).
The effect of Wnt3a on IR transcription
was further assayed in HEK cells by IR
promoter-dependent expression of lucif-
erase (Figure 5D). There was a significant
increase in IR promoter-dependent
expression of luciferase after 8 hr stimula-
tion with Wnt3a. The role of TCF7L2 in IRtranscription was examined in 3T3L1 cells treated with PBS or
Wnt3a by chromatin immunoprecipitation (ChIP) using a specific
antibody. Binding of TCF7L2 to the IR promoter was verified by
real-time PCR using IR promoter-specific primers. The ChIP anal-
ysis showedenhancedbinding of TCF7L2 to the IRpromoter upon
stimulation with Wnt3a compared to vehicle alone (Figure 5E,
upper and lower panels). The electrophoretic mobility shift assay
(EMSA) analysis using nuclear extracts of the 3T3L1 cells treated
withWnt3ashowedbindingofTCF7L2 to theTCFconsensusmotif
in the IR promoter and a supershift after using a ChIP-grade anti-
body (Figure 5F). Taken together, these findings establish the
role of TCF7L2 as a transcription regulator of the IR with major
implications for therapy in diabetes, particularly in patients with
TCF7L2 variants.
TCF7L2 overexpression in skin fibroblasts of LRP6R611Cmuta-
tion carriers fully restored IR expression (Figure S4A) and insulin
signaling (Figures S4B and S4C). This finding once again under-
scores the biological importance of this transcription factor in
regulation of IR transcription and insulin signaling in humans.
mTORC1-Dependent IRS-1 Serine Phosphorylation
Contributes to Insulin Resistance
Mechanisms that regulate glucose metabolism are linked
through numerous intricate molecular pathways, raising the
possibility that the R611Cmutation may have other effects on in-
sulin signaling and glucose homeostasis. This assumption was
Figure 3. LRP6 Knockdown Reduces IR Transcription and Impairs Insulin Signaling
(A and B) mRNA interference using LRP6-specific shRNA in 3T3L1 preadipocytes reduced expression of LRP6 bymore than 90% (A) and reduced expressions of
IR protein (A) and mRNA (B) by greater than 50%.
(C) IR quantification by densitometry.
(D) In LRP6 knockdown 3T3L1 adipocytes there was a reduced response to insulin stimulation assayed by phosphorylation of IRS-1, AKT, and GSK-3b.
(E–G) Quantification of IRS-1 (E), p-AKT (F), and p-GSK3b (G) by densitometry (*p < 0.05, **p < 0.005, ***p < 0.001). Error bars represent SD. Open circles
represent the control, and black squares represent the mutant.
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Wnt/LRP6 Regulation of IR and IGFRfurther supported by increased IRS-1 serine phosphorylations in
response to insulin in LRP6R611C versus wild-type fibroblasts
(Figure 6A). Increased phosphorylation of IRS-1 on multiple
serine residues (S307, S612, S636/S639, and S1101) in
LRP6R611C fibroblasts suggested alteration in the function of
mTORC1, a major regulator of insulin signaling and metabolism
(Mothe and Van Obberghen, 1996). LRP6R611C fibroblasts ex-
hibited significantly higher S6K and S6 phosphorylations
compared to wild-type fibroblasts, suggesting enhanced
mTORC1 activity. Increased mTORC1 activity correlated with
increased ERK1/ERK2T202/Y204 phosphorylation in LRP6R611C
fibroblasts compared to wild-type fibroblasts.
Insulin increases the activity of ERK1/ERK2 via the IR and
insulin-like growth factor receptor (IGFR). While IR expression
was significantly reduced in LRP6R611C fibroblasts as previously
shown, IGFR expression was significantly increased in these
cells compared to wild-type fibroblasts (Figure 6A). Consistent
with these findings, LRP6 knockdown by RNA interference re-
sulted in increased expression of IGFR and activity of the
mTORC1 pathway (Figure 6B). The significance of the mTOR
pathway in IRS-1 serine phosphorylation was investigated by
treating human skin fibroblasts with mTORC1 antagonist rapa-
mycin for 48 hr. IRS-1 phosphorylation at these residues signifi-Cell Mcantly decreased in response to insulin in LRP6R611C fibroblasts
treated with rapamycin (Figure 6C).
IGFR mRNA was significantly reduced in LRP6 knockdown
cells compared to cells infected with vector alone (Figure 6D)
suggesting posttranscriptional regulation of IGFR by LRP6.
Accordingly, protein levels rose to similar levels in both cell types
after treatment with proteasomal inhibitor MG-132 (Figure 6E),
indicating IGFR ubiquitination by LRP6. Earlier studies have
shown that IGFR is a target of sumoylation (Sehat et al., 2010),
a process that may render stability to the protein. Coimmunopre-
cipitation studies in 3T3L1 cells treated with IGF-1 revealed that
IGFR and SUMO-1 (small ubiquitin like-modifier 1) form
a complex in LRP6 knockdown cells (Figure 6F). These findings
provide strong evidence that LRP6 regulates the nutrient-
sensingmTOR pathway through a tight network, and impairment
of this regulation by the LRP6R611C mutation results in excess
ERK1/ERK2-dependent mTORC1 activity and IRS-1 serine
phosphorylation at multiple residues.
DISCUSSION
We have previously reported a nonconservative mutation in
Wnt coreceptor LRP6 (R611C) that underlies autosomaletabolism 17, 197–209, February 5, 2013 ª2013 Elsevier Inc. 201
Figure 4. LRP6-Dependent IR Transcription Is Mediated by the Canonical Wnt Signaling
(A and B) Stimulation of 3T3L1 preadipocytes by Wnt3a (30 ng/ml) resulted in a continuous rise of IR mRNA (A) and protein levels (B), reaching a maximum at 8 hr
poststimulation; b-catenin and cyclin D1 were used as positive controls.
(C) IR, cyclin D1, and b-catenin quantifications by densitometry are shown. Open circles represent IR, black squares represent b-catenin, and grey triangles
represent cyclin D1.
(D) The stimulatory effect of Wnt3a (30 ng/ml) on IR transcription was completely blunted when LRP6 was knocked down.
(E) LiCl (20 mM/ml) treatment of the 3T3L1 cells significantly rescued IR expression.
(F) Noncanonical stimulation of 3T3L1 cells with Wnt5a (50 ng/ml), in contrast to Wnt3a, did not have any effect on IR-b expression.
(G) The role of canonical Wnt signaling in IR expression was further investigated by lentivirus shRNA knockdown of b-catenin in 3T3L1 cells, which resulted in
lower expression of IR-b compared to GFP-shRNA. *p < 0.05, **p < 0.005, ***p < 0.001). Error bars represent SD.
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Wnt/LRP6 Regulation of IR and IGFRdominant early onset atherosclerosis, diabetes, and metabolic
syndrome (Keramati et al., 2011; Mani et al., 2007; Ye et al.,
2012). In the current study we demonstrate that healthy
LRP6R611C mutation carriers suffer from impaired skeletal202 Cell Metabolism 17, 197–209, February 5, 2013 ª2013 Elsevier Inmuscle insulin signaling prior to development of impaired
glucose tolerance or diabetes.
Dissection of the insulin signaling pathway in the skeletal
muscle of LRP6R611C mutation carriers with NGT revealedc.
Figure 5. TCF7L2 Regulates IR Expression
(A and B) Lentivirus shRNA knockdown of TCF7L2 reduced expression of IR-b in 3T3L1 preadipocytes (A) and human skin fibroblasts (B) compared to
GFP-shRNA.
(C) Accordingly, TCF7L2 overexpression in 3T3 L1 cells resulted in enhanced IR expression, which was further augmented with Wnt3a stimulation.
(D) A luciferase-based reporter gene assay in HEK293 cells using the IR promoter showed a 1.5- to 2-fold increase in luciferase activity starting at 8 hr after Wnt
stimulation compared to empty vector.
(E) ChIP revealed binding of TCF to a specific promoter region of IR; IgG was used as negative control. Top figure shows relative binding of the IR promoter
precipitated with either TCF7L2 or IgG antibody before and after treatment with Wnt3a; lower panel shows agarose gel pictures of the PCR products. H3 stands
for histone 3.
(F) EMSA demonstrating TCF7L2 binding to a TCF consensus motif in the IR promoter using nuclear extracts from 3T3L1 cells 30 min after Wnt3a stimulation.
Lane 1, probewith no extract; lane 2, probewith nuclear extract; lane 3, probewith nuclear extract and excess of nonbiotinylated probe; lane 4, probewith nuclear
extract and IgG as control; lane 5, probe with nuclear extract and TCF7L2 antibody showing the supershift. Error bars represent SD.
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Wnt/LRP6 Regulation of IR and IGFRmarkedly reduced expression of the skeletal muscle IR as one
of the underlying causes of insulin resistance. The IR and its
downstream effectors constitute an evolutionarily highly
conserved pathway, and perturbation of their expression and
function has been linked to insulin resistance. Reduced tran-Cell Mscription of IR has previously been described in type A insulin
resistant subjects with mutations in the IR gene (Kadowaki
et al., 1988; Kahn et al., 1976; Kahn and White, 1988; Kriauciu-
nas et al., 1988; Ojamaa et al., 1988). The affected individuals
exhibit extremely high circulating insulin levels in early yearsetabolism 17, 197–209, February 5, 2013 ª2013 Elsevier Inc. 203
Figure 6. Enhanced ERK1/ERK2-Depen-
dent Activation of mTOR Results in IRS-1
Serine Phosphorylation at Several Residues
(A) Increased expression of IGFR results in
enhanced ERK1/ERK2-dependent activation of
mTORC1 and enhanced phosphorylation of IRS-1
at several serine residues in skin fibroblasts of
LRP6R611C mutation carriers compared to
noncarriers.
(B) LRP6 knockdown increases IGFR expression
and results in mTOR-dependent IRS-1 phos-
phorylation at several serine residues.
(C) Rapamycin treatment of the skin fibroblasts of
LRP6R611C mutation carriers significantly reduces
IRS-1 serine phosphorylation.
(D) ***p < 0.001. IGFR protein (B), but not mRNA
levels (D), are higher in LRP6 knockdown
compared to vector alone.
(E) IGFR protein expression rose to similar levels
after treatment with proteasomal inhibitor MG-132
(5 mm/ml) for 8 hr.
(F) SUMO-1 was immunoprecipitated and IGFR
was immunoblotted with specific antibody and
vice versa before and after treatment of cells with
IGF-1 (100 nM/ml) for 8 hr. IGFR was coimmuno-
precipitated with SUMO-1 to a significantly
greater degree in LRP6 knockdown cells com-
pared to vector alone. Arrows show bands that
correspond to IGFR. Error bars represent SD.
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diabetes. In contrast, reduced IR expression in ob/ob and db/
db mice is due to defects in posttranscriptional regulations
(Ludwig et al., 1988).
There is relatively little known about the transcriptional regu-
lation of the IR (McKeon, 1993). HMGI(Y) and FOXO1 have
recently been shown to be transcriptional regulators of IR (Bru-
netti et al., 2001; Puig and Tjian, 2005). HMGI(Y) is a Wnt/b-cat-
enin inducible protein (Akaboshi et al., 2009), which together
with TCF7L2 belongs to the HMG domain family of DNA-
bending proteins (van Houte et al., 1993), and FOXO1 is
a pluripotent transcription factor activated by Wnt/b-catenin
(Essers et al., 2005). Our studies identified TCF7L2 as a potent
transcriptional regulator of the insulin receptor. Genome-wide
association studies have associated a minor TCF7L2 (formerly
known as TCF4) allele with the risk for type 2 diabetes. The
minor allele has been linked to reduced TCF7L2 protein
expression and impaired insulin signaling (Yoon et al., 2010).
The effect imparted by this variant on insulin signaling is inher-
ently too small to be measurable in biological systems (Liu
et al., 2009; Lyssenko et al., 2007). In contrast, the effect of
R611C mutation on blood glucose is substantial, allowing care-204 Cell Metabolism 17, 197–209, February 5, 2013 ª2013 Elsevier Inc.ful investigation of Wnt, insulin signaling,
and the interplay between them. This led
to the key finding that Wnt-b-catenin
activation triggers the binding of
TCF7L2 to a TCF/LEF binding motif
within the IR promoter and enhances
transcription of IR. The TCF binding
motif is abundantly present in 50 and 30
regulatory regions of the IR and ishighly conserved from Drosophila to mammals, indicating the
important role of TCFs in transcriptional regulation of IR. The
restoration of IR expression and insulin signaling in the skin
fibroblasts of LRP6R611C mutation carriers by TCF7L2 overex-
pression further confirmed the biological importance of this
transcription factor in regulation of IR transcription and insulin
signaling in humans.
LRP6R611Cmutation likely has multifaceted effects on glucose
homeostasis (Figure 7). Dissection of insulin signaling in the skin
fibroblasts of LRP6R611C mutation carriers showed that this
mutation also impairs insulin signaling by phosphorylation of
IRS-1 at multiple serine residues. IRS-1 serine phosphorylations
are regulated by different kinases. Raptor-mTOR and S6K1,
however, are required for phosphorylation of IRS-1 at a large
subset of serine residues (Shah and Hunter, 2006). mTORC1 is
activated by insulin as well as growth factors like IGF-1. Our find-
ings suggest that impaired ubiquitination of IGFR by the mutant
LRP6 results in enhanced expression and activities of IGF-mTOR
pathways. High insulin levels in the presence of marked reduc-
tion of IR likely exacerbate this effect.
Taken together, our investigations provide mechanisms by
which Wnt regulates insulin signaling in preadipocytes and
Figure 7. Schematic of Wnt/LRP6 Signaling, Its Role in Regulation of IR and IGFR Ubiquitination, and the Effect of LRP6 Mutation on These
Functions
(A) LRP6 mediates Wnt3a activation and binding of TCF7L2 to the TCF/LEF binding motif within the IR promoter, enhances transcription of IR, and promotes
insulin signaling. Furthermore, it regulates IGFR expression by promoting its ubiquitination.
(B) The mutant LRP6 protein sumoylates IGFR and increases its stability. IGFR enhances ERK1/ERK2-dependent mTOR activity. mTOR phosphorylates IRS-1 at
several serine residues and promotes its ubiquitination. In addition, mutant protein impairs Wnt signaling and diminishes TCF7L2-dependent IR transcription.
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insulin signaling in preadipocytes had been reported without
elaborating the mechanisms (Palsgaard et al., 2012). By dissect-
ing insulin signaling pathways in mutant and wild-type primary
human cells, we discovered that Wnt/LRP6 regulate IR and
IGFR expressions via two independent mechanisms. Through
rigorous investigations we demonstrated that Wnt signaling
regulates transcription of IR, while its coreceptor LRP6 regulates
IGFR by ubiquitination.
In this study we focus on the earliest effects of the LRP6R611C
mutation on skeletal muscle insulin signaling before mutation
carriers develop apparent signs of impaired glucose tolerance.
Since LRP6 is ubiquitously expressed, parallel changes in IR
expression of the liver and pancreas tissues of the mutation
carriers may occur. While the abnormalities we demonstrate
here are limited to the skeletal muscle, reduced IR expression
in the liver and/or beta cells may similarly contribute to hypergly-
cemia later in the disease course. Lack of access to these tissues
is a limitation of our study.
Our physiological studies may also have been underpow-
ered to show subtle effects of the mutation on hepatic glucose
production at the very early stage of the disease. Furthermore,
other LRP6 mutations may primarily impair hepatic insulin
sensitivity or beta cell function. Larger studies involving
carriers of different LRP6 mutations as well as animal models
may provide further information on the effects of Wnt signaling
on glucose homeostasis. In summary, our study presents
molecular pathways that link Wnt signaling to insulin action
in the skeletal muscle, providing significant insight into
pathogenesis of metabolic syndrome. Through molecular
dissection of these pathways we have identified a number of
potential targets for the development of therapeutics against
insulin resistance ranging from LRP6 and IGFR/mTORC1 to
TCF7L2.Cell MEXPERIMENTAL PROCEDURES
Study Population
The original R611C kindred was extended to 48 mutation carriers and 44
noncarriers. Healthy nondiabetic members of the family were asked to partic-
ipate in the study. Among these individuals, eight LRP6R611Cmutation carriers
(six male, two female) and seven nondiabetic nonmutation carrier family
members (five male, two female) were enrolled. Each volunteer was free of
major medical problems, based upon clinical evaluations, and was not taking
prescription medications. All probands underwent physical examination,
blood testing, and an OGTT followed by skeletal muscle and skin punch
biopsies. The institutional review board at the Yale University School of Medi-
cine and the Tehran University of Medical Sciences and Shahid Motahari
Hospital approved the research protocol; all study participants provided
written informed consent for clinical and genetic studies.
OGTT and Euglycemic-Hyperinsulinemic Clamp Studies
Glucose tolerance was assessed by administration of a 75 g dextrose drink
(Glucola, Curtin Matheson Scientific, Houston). Blood samples for measure-
ment of plasma glucose and insulin concentrations were obtained at 0, 15,
30, 45, 60, 90, and 120 min and used to estimate the insulin sensitivity index
(ISI). ISI was calculated by the formula ISI = 10,000 / sqrt (FPG 3 FPI) 3
(G 3 I); FPG is fasting plasma glucose, FPI is fasting plasma insulin, and
G and I are average glucose and insulin concentrations during the OGTT
(Matsuda and DeFronzo, 1999).
A selected number of the LRP6R611Cmutation carriers (n = 3) and noncarriers
(n = 3) agreed to participate in euglycemic-hyperinsulinemic clamp studies.
These subjects were admitted to the Yale-New Haven Hospital Research
Unit of the Yale Center for Clinical Investigation (YCCI) on the day of the study
after an overnight fasting. Two indwelling venous catheters were inserted. One
was inserted into a distal arm or hand vein that was placed in a heated box to
allow for the sampling of arterialized venous blood. The second venous
catheter was used for the administration of a primed (200 mg/m2) and contin-
uous infusion of 6,6 D2-glucose (2 mg/[min 1]3 [m 2]) as well as for taking
blood samples for insulin and glucose measurements. After the basal equili-
bration period lasting 2 hr, a sequential two-step euglycemic-hyperinsulinemic
clamp study was performed (Mayerson et al., 2002) during which regular
insulin was administered as a primed-continuous infusion at 10 and 80 mU/
(m2 3 min), each for 120 min. Plasma glucose levels were measured atetabolism 17, 197–209, February 5, 2013 ª2013 Elsevier Inc. 205
Cell Metabolism
Wnt/LRP6 Regulation of IR and IGFR5 min intervals, and a variable glucose infusion was initiated to maintain levels
at 90 mg/dl. Additional plasma samples were drawn at baseline and
throughout the insulin infusion period for measurement of isotope enrichment,
insulin, FFA, and glycerol turnover. One of the LRP6R611C mutation carriers
only received the higher insulin infusion dose (i.e., 80 mU/[m2 3 min]) for
120 min.
Skeletal Muscle and Skin Biopsies
Skeletal muscle biopsies were obtained from M. vastus lateralis of mutation
carrier and noncarrier relatives according to the technique of Bergstro¨m (Berg-
stro¨m et al., 1967). The first biopsates were quickly frozen in Allprotect Tissue
Reagent (QIAGEN) for later protein and mRNA quantification. Skin biopsies
were also obtained and immediately placed in culture medium. Subsequently,
fibroblasts were harvested by isolating dermis followed by fragmentation and
placement in 20 mm grid Petri dishes.
Analytical Procedures
Plasma glucose concentrations were measured by the glucose oxidase
method (Glucose Analyzer II; Beckman Instruments, Fullerton, CA), and
plasma insulin was determined using a Double Antibody RIA (Diagnostic
Systems Laboratories, Inc., Webster, TX). Glucose isotope data was acquired
by a chromatography mass spectrometer at the DERC Stable Isotope Core
Laboratory. Glucose kinetics were determined in the basal state and during
euglycemic hyperinsulinemia (Sherwin et al., 1974). Total body glucose
disposal during the clamp study was calculated as the sum of endogenous
glucose production and the exogenous glucose infusion rate (GIR) in the final
30 min of each infusion dose.
Chemicals
Insulin, dexamethasone, 3-isobutyl-1-methylxanthine, puromycin, protease
inhibitor cocktail (P8340), phosphatase inhibitor cocktail (P2850), phenylme-
thanesulfonyl fluoride (P7626), rapamycin (R8781), and LiCl were purchased
from Sigma-Aldrich (St. Louis). Cell Lysis Buffer (9803) and ChIP Kit (9003S)
were obtained from Cell Signaling Technology (Boston). The lentiviral LRP6
shRNA(h) (sc-37233-v), LRP6 shRNA(m) (sc-37234-v), b-catenin shRNA
(sc-29210-v), TCF-4 (TCF7L2) shRNA (sc-43526-v), control shRNA (sc-
108080), and polybrene were purchased from Santa Cruz Biotechnology,
Inc. (Santa Cruz, CA). Wnt3a (1324-WN) andWnt5a (645-WN) were purchased
from R&D Systems; Dulbecco’s modified Eagle’s medium (DMEM), fetal
bovine serum (FBS), penicillin streptomycin cocktail, Trypsin-EDTA solution,
and TRIzol from GIBCO/Invitrogen; and polyvinylidine fluoride (PVDF) mem-
branes from Bio-Rad Laboratories (Hercules, CA).
Antibodies, Cell Lines, and Adipocyte Differentiation
Antibodies for LRP6, p-LRP6(S1490), IR-b, Akt, p-Akt(S473), IRS-1, GSK-3b,
p-GSK-3b(S9), b-catenin, cyclin D1, GAPDH, b-actin, IRS-1-P(S307), IRS-1-
P(S1101), IRS-1-P(S636/S639), IRS-1-P(S612), S6 ribosomal protein-p(S235/S236),
S6 ribosomal protein, p70 S6 Kinase-P(T389), p70 S6 Kinase, mTOR,
mTOR-P(S2448) p44/42 ERK1/ERK2-P(T202/Y204), p44/42 ERK1/ERK2, IGFR,
p-IGFR(Y1316), SUMO-1, and Ubiquitin were purchased from Cell Signaling
Technology. Antibodies for IR-b (C-19), TCF-4 (TCF7L2) (sc-8631), LRP6
(C-20), HMGI(Y), IRS-1-P(S265/270) were purchased from Santa Cruz Biotech-
nology, Inc.. Antibodies for p-IRS-1(Y612) were purchased from Invitrogen
Life Technology (ON, Canada). The specificity of the commercial IR antibodies
has been confirmed previously (Cheung et al., 2010). Human skin fibroblasts,
murine 3T3L1 cells, and human embryonic kidney (HEK) 293 cells were grown
in DMEM supplemented with 10% FBS and 1% (v/v) penicillin/streptomycin
cocktail. HEK293T cells were used for lentivirus production. 3T3L1 cells
(0.53 106/well) were plated on 6-well plates 1 day before infection. Polybrene
(5 mg/ml) and lentivirus particles were added into the medium. On day 2
following transduction, the medium was replaced with medium supplemented
with 5 mg/ml of puromycin. Untransduced dead cells were removed on day 2,
and live cells were further expanded and maintained in DMEM supplemented
with 10% FBS and 1% (v/v) penicillin/streptomycin cocktail.
The 3T3L1 preadipocytes were differentiated into adipocytes by culturing
with DMEM supplemented 10% FBS, 1 mg/ml insulin, 1 mM dexamethasone,
and 0.5 mM isobutylmethylxanthine for 48 hr and then for an additional 48 hr
with DMEM supplemented with 10% FBS and 1 mg/ml of insulin. Subse-206 Cell Metabolism 17, 197–209, February 5, 2013 ª2013 Elsevier Inquently, the cells were refed every 48 hr with DMEM containing 10% FBS.
For differentiation of skin fibroblasts, 0.2 mM indomethacin was added to
the cocktail as described earlier (Lysy et al., 2007); cells were treated with
this cocktail for 28 days. Medium was changed every 4 days. At completion
of differentiation, adipogenesis was examined by oil red O staining. The stim-
ulation experiments were carried out after culturing the differentiated cells for
24 hr in DMEM supplemented with 0.2% FBS.
Immunoprecipitation and Immunoblotting
Whole-cell lysates from human muscle biopsies and cultured cell lines were
prepared using cell lysis buffer (CST #9803) supplemented with 4 ml/ml of
protease inhibitor cocktail, 10 ml/ml of phosphate inhibitor, and 1mM phenyl-
methanesulfonyl fluoride (PMSF). Bio-Rad protein assay reagent was used
to measure protein concentration. For coimmunoprecipitation, 500 mg of total
protein was immunoprecipitated with the appropriate antibodies for overnight
and protein A/G agarose beads for 1 hr at 4C. Proteins were solubilized in
Laemmli sample loading buffer and resolved by SDS-PAGE. Protein was trans-
ferred to a PVDF membrane and immunoblotted using different primary anti-
bodies. Appropriate HRP-conjugated secondary antibodies and enhanced
chemiluminescence reagents were used to develop the blots.
Real-Time PCR
Total RNA was isolated from human muscle biopsies and cultured cells using
TRIzol (Invitrogen), and complementary DNA (cDNA) was generated using
a High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) accord-
ing to the manufacturer’s instructions. Real-time PCR amplification was per-
formed using iQ SYBR Green Supermix (Bio-Rad) in Eppendorf Mastercycler
RealPlex2 after adjusting the threshold cycle (Ct). Reactions were performed
in quadruple with a b-actin internal control. Relative quantification of mRNA
levels was expressed as fold increase relative to the control.
ChIP assay
ChIP was performed according to the manufacturer’s instructions (Cell
Signaling Technology, 9003S). Briefly, the chromatin/DNA protein complexes
were prepared from 3T3L1 cells treated with vehicle (PBS with 0.1% BSA) or
Wnt3a (30 ng/ml) for 2 hr. Chemical crosslinking of DNA-proteins was carried
out using 1% formaldehyde for 10 min at room temperature. The crosslinking
was quenched by addition of glycine (0.125 M) for 5 min at room temperature
and followed by two washes with ice-cold PBS. Cells were scraped into
PBS containing 1 mM PMSF. The cell suspension was centrifuged and the
pellet was mixed by inverting the tube every 3 min in buffer A + DTT +
PIC + PMSF followed by incubation on ice for 10 min. The pellet (nuclei)
was dissolved in 1.0 ml buffer B + DTT + 5 ml of micrococcal nuclease and
incubated for 20 min at 37C with frequent mixing to digest DNA to a length
of approximately 150–900 bp. The lysate was incubated with appropriate
ChIP-grade TCF-4 (TCF7L2) antibody (sc-8631, Santa Cruz Biotechnology,
Inc.) to immunoprecipitate chromatin overnight at 4C with rotation and fol-
lowed by ChIP-grade protein G magnetic beads and incubation for 2 hr at
4C with rotation. The magnetic beads were washed using buffers supplied
with the kit. The eluted DNA was purified and analyzed by PCR to determine
the binding of TCF7L2 to the IR promoter. PCR primers were designed by
using the criteria described in the kit. The region of the mouse IR promoter
from 550 to 900 bp was taken to design the primers and found to bear
the putative TCF7L2 binding site (consensus sequence: AGATCAAAGGG)
(van de Wetering et al., 1997) identified by online transcription factors
binding prediction software (PROMO 3.0; http://alggen.lsi.upc.es and
http://searchlauncher.bcm.tmc.edu/seq-search/alignment.html). The follow-
ing primers were used for Mouse IR-P-forward (F) 50-TAAGACATTGGTAGC
ATAGGCTGT-30, Mouse IR-P-reverse (R) 50-CCAAGCACATTTTGTCTTTCT
TTA-30. The control primers for mouse RPL30 were provided with the kit.
Real-time PCR amplification was performed using iQ SYBR Green Supermix
(Bio-Rad) and Eppendorf Mastercycler RealPlex2.
Electrophoretic Mobility Shifting Assay
EMSA was carried out to determine the binding of TCF7L2 to the 65 bp
IR promoter region 50-GTAGCATAGGCTGTAAAGAAAAACAGAATCAAAGG
TAAAGAATTAAAGTGAATTCCCCACGGGAG-30 (corresponding to nt posi-
tion 694 to 759) bearing one putative TCF7L2 recognition site. Thec.
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Synthesis Facility of Yale University. The DNA fragment was labeled using the
Biotin 30 End DNA Labeling Kit (Thermo Scientific). Nuclear extracts were
prepared using the NE-PER Nuclear Extraction Reagent Kit (Thermo Scien-
tific). The binding reactions (20 ml reaction mix) were incubated for 20 min at
room temperature using the LightShift EMSA Kit (Thermo Scientific) with
a 20 fM concentration of labeled duplex DNA, 3 mg of nuclear protein extract,
binding buffer, 50 ng/ml poly(dI-dC), 0.5% NP-40, 2.5% glycerol, and 5 mM
MgCl2 (concentrations based on the manufacturer’s recommendations). For
antibody supershift, 1 ml of TCF7L2-specific ChIP grade (C-19, Santa Cruz
Biotechnology, Inc.) and 1 ml of nonspecific control IgG antibodies were incu-
bated with nuclear extract proteins for 30 min at room temperature prior to
addition of labeled probes. After mixing with 5 ml of loading buffer, the reaction
mix was immediately loaded on 5% native agarose gel in 0.53 Tris-borate-
EDTA (TBE) that was pre-electrophoresed in 0.53 TBE followed by electro-
phoresis and then electrophoretically transferred onto a positively charged
nylon membrane (Thermo Scientific) in 0.53 TBE. The DNA-protein complex
onmembrane was crosslinked by UV and visualized with a Horseradish Perox-
idase-Conjugated Streptavidin Kit (Thermo Scientific) according to the manu-
facturer’s instructions.
Construct and Luciferase Assay
pIRP-GLuc plasmid for the IR promoter was constructed as described previ-
ously with some modifications (Dasgupta et al., 2011). Briefly, the IR promoter
sequence was amplified by PCR using phINSRP-1 as a template with forward
(50- GGGGGAATTCGGCCATTGCACTCCA-30) and reverse (50-AATTGGATC
CTGCGGGAGCGCGGGG-30) primers. The PCR product was cloned into the
TOPO vector according to the manufacturer’s protocol (TOPO TA Cloning
Kits, Invitrogen). The cloned insert was removed from the TOPO vector by
digestion with EcoRI/BamHI and subcloned in the pGLuc vector yielding
pIRP-GLuc. The cloned IR promoter construct was confirmed by sequencing.
HEK293 cells were transfected for 48 hr with pIRP-GLuc plasmid using
X-tremeGENE HP DNA Transfection Reagent (Roche Applied Science, Indian-
apolis, IN, USA), and luciferase activity was measured after stimulation with
recombinant Wnt3a for different time points using BioLux Gaussia Luciferase
Assay Kit (New England Biolabs, Inc.).
Rescue Studies
To further confirm that the transcription regulation of IR is Wnt dependent,
LRP6 knockdown 3T3L1 cells were treated with LiCl for 24 hr followed by stim-
ulation with Wnt3a for different time courses. We examined the effect of TCF
on IR transcription by permanent expression of TCF7L2 in 3T3L1 cells and
human skin fibroblasts. For this purpose a retrovirus vector (LXSN, Clonetech)
containing TCF7L2 cDNA using plasmid 16514 (Addgene) (Korinek et al., 1997)
as a template was generated. Cells were infected with either TCF7L2-contain-
ing or empty vectors. Cells were serum starved and stimulated by wnt3a for
different time courses and harvested for analysis. To rescue mTORC1-depen-
dent IRS-1 serine phosphorylation, human mutant and wild-type fibroblasts
were treated with 100 nM/ml mTORC1 inhibitor rapamycin for 48 hr and stim-
ulated with insulin.
Statistical Analysis
All laboratory-based experimental data represent results from four indepen-
dent experiments. Sample size was calculated to provide sufficient power to
detect a 30% difference in the basal rate of glucose disposal rate (GDR)
between nondiabetic and diabetic subjects. Sample size justifications were
based on ANOVA and an alpha of 0.05 using the formula
N=
2ðZa+ZbÞ2ðsÞ2
D2
;
where N is the required sample size, Za and Zb are the false positive and false
negative error rates tolerated, respectively, (Za = 1.96, 95%, two-tailed; Zb =
1.28, 90%, one-tailed), s2 is the variance based on prior studies (square of the
SD), and D is the difference in the primary endpoint (GDR). This is based on
previous studies in normal control subjects (n = 7).
N=
2ð3:24Þ2ð23Þ2
ð76:8Þ2 = 1:88Cell MProtein expression levels were quantified by densitometry of western blots.
All statistical analyses, including clinical data, were carried out with two-factor
analysis of variance (ANOVA). Statistical comparisons were done using
GraphPad Prism 5 software. A p value of < 0.05 was considered statistically
significant. Error bars represent SD.
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